Cardio IQ® 4q25‑AF Risk Genotype
Also known as: Atrial Fibrillation (AF), CardioIQ®, 4q25-AF Risk Genotype, rs10033464, rs2200733
Use
This test aids physicians in the assessment of risk of atrial fibrillation (AF) and cardioembolic stroke. Carriers of risk variants at 4q25 may have up to approximately 1.7‑fold increased risk of AF and up to approximately 1.5‑fold increased risk of cardioembolic stroke related to AF. Developed and performed by Quest Diagnostics Nichols Institute, this CLIA‑certified and CAP‑accredited laboratory test has not been cleared or approved by the FDA. It may help inform clinical follow‑up decisions in patients with potential predisposition to AF.
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
PCR-based (PCR)
Biomarkers
LOINC Codes
- 8251-1
- 92935-6
- 92936-4
- 69426-5
- 77202-0
- 49549-9
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4 mL
Minimum Volume
2 mL
Container
EDTA (lavender‑top) tube
Collection Instructions
Follow normal phlebotomy procedures; multiple (up to 8) cardiovascular‑related genetic tests can be performed on a single specimen; a second EDTA tube is required if non‑genetic EDTA tube tests ordered simultaneously.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 days |
| Refrigerated | 8 days |
| Frozen | 30 days |